Authors
Latest:
Dr. Chen on FLASH Trial Results in CTCLPei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.
Latest:
Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder CancerR. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.
Latest:
Dr. Shah on the Importance of Genetic Testing in GI CancerManish A Shah, MD, discusses the importance of genetic testing in gastrointestinal cancer.
Latest:
Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCCJoseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Latest:
Dr Ronai on Key Advances in Melanoma Treatment ApproachesZe'ev Ronai, PhD, discusses key advancements in the treatment of patients with melanoma, including the discovery of NRAS and BRAF mutations, as well as the development of immunotherapy approaches.
Latest:
Garvin on the Benefits of CAR T-Cell Therapy in Non-Hodgkin LymphomaKelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.
Latest:
Dr Fonkoua on Addressing Barriers to Cancer Clinical Trial AccessLionel A. Kankeu Fonkoua, MD, discusses the importance of addressing barriers to clinical trial access that patients with cancer may face and increasing patient access to routine, primary care.
Latest:
Dr. Thompson on the Rationale for the BRUIN Study in Richter TransformationMeghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.
Latest:
Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial CancerThe activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.
Latest:
Dr Miller on the Importance of Patient Advocacy in Gynecologic OncologyEirwen M. Miller, MD, discusses the importance of advocating for women in gynecologic oncology on International Women’s Day.
Latest:
Truong on the Rationale for Investigating ERK2 Substrate Binding Modalities in MPNsBilly Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.
Latest:
Using Systemic Therapy to Treat HER2+ Breast CancerClosing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Latest:
Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the LungKathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.
Latest:
Leveraging Immunotherapy in GI Malignancies: Looking to the FutureIn this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Latest:
Dr. Hunt on Axillary Reverse Mapping in Breast CancerKelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.
Latest:
Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic MelanomaThe recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.
Latest:
Dr Jayram on the Role of Immunotherapy in Bladder CancerGautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.
Latest:
Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer DiagnosisNicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.
Latest:
Sequencing Throughout Multiple Lines of Therapy in RR DTCBefore closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
Latest:
Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALLShannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Latest:
Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI CancersRondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.
Latest:
Targeting the PI3K Pathway in HR+/HER2- MBCThe rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.
Latest:
RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance ProgramThe incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.
Latest:
Dr. Kris on Immunotherapy in NSCLC Without Driver MutationsMark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.
Latest:
Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast CancerAddressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.
Latest:
Dr. Shirasu on the Clinical Implications of ctDNA in CRCHiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.
Latest:
Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast CancerKevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.
Latest:
Dr Jones on Clinical Fracture Incidence in mHSPCCraig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.
Latest:
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial CancerRebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
